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ABSTRACT Human parvovirus B19 (here B19), human cytomegalovirus (HCMV), and
Toxoplasma gondii infections during pregnancy can lead to severe complications. While
traditional diagnosis of infections is mostly confined to one pathogen at a time, a multi-
plex array is a feasible alternative to improve diagnostic management and cost-
efficiency. In the present study, for these three pathogens, we developed microsphere-
based suspension immunoassays (SIAs) in multiplex and monoplex formats for the
detection of antimicrobial IgM antibodies as well as corresponding chaotrope-based IgG
avidity SIAs. We determined the diagnostic performances of the SIAs versus in-house
and commercial reference assays using a panel of 318 serum samples from well-
characterized clinical cohorts. All the newly developed assays exhibited excellent perfor-
mance compared to the corresponding high-quality reference methods. The positive
and negative percent agreements of the IgM SIAs in comparison with reference meth-
ods were 95 to 100% and 98 to 100%, and those of the IgG avidity SIAs were 92 to
100% and 95 to 100%, respectively. Kappa efficiency values between the SIAs and the
corresponding reference assays were 0.91 to 1. Furthermore, with another panel com-
prising 391 clinical samples from individuals with primary infection by B19, HCMV, or T.
gondii, the IgM SIAs were highly sensitive for the detection of acute infections, and the
IgG avidity SIAs were highly specific for the separation of primary infections from past
immunity. Altogether, the strategy of IgM multiplex screening followed by IgG avidity re-
flex testing can provide high-throughput and accurate means for the detection and
stage determination of B19, HCMV, and T. gondii infections.
IMPORTANCE Human parvovirus B19, human cytomegalovirus, and Toxoplasma gondii
are ubiquitous pathogens. Their infections are often asymptomatic or mild in the gen-
eral population yet may be transmitted from mother to fetus during pregnancy. Mater-
nal infections by these pathogens can cause severe complications to the fetus or con-
genital abnormalities. As a rule, the risk of maternal transmission is critically related to
the infection time; hence, it is important to determine when a pregnant woman has ac-
quired the infection. In this study, we developed new diagnostic approaches for the tim-
ing of infections by three pathogens. All the new assays appeared to be highly sensitive
and specific, providing powerful tools for medical diagnosis.
KEYWORDS intrauterine infection, B19, HCMV, T. gondii, IgM, IgG avidity, suspension
immunoassay, multiplex, infection time
Human parvovirus B19 (here B19), human cytomegalovirus (HCMV), and Toxoplasmagondii cause infections worldwide. Although these infections are usually asymp-
tomatic in immunocompetent individuals, they can lead to severe complications during
pregnancy. Maternal B19 infection can cause spontaneous abortion, fetal hydrops, and
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intrauterine death (1, 2), whereas HCMV and T. gondii can cause central nervous system
damage in the fetus and can lead to long-term sequelae, including sensorineural
hearing loss and chorioretinitis, respectively (3, 4). As a rule, with many microbes,
acquired primary, as opposed to secondary, maternal infection carries the highest
maternofetal transmission rate (4–6). With B19, fetal complications tend to occur by the
second trimester (7), and with HCMV or T. gondii, transplacental transmission is more
frequent during late gestation (8–10), whereas the incidence of severe congenital
disease is higher in early pregnancy (11, 12).
Since the risk to the fetus is critically related to the infection time, it is essential to
accurately determine whether a pregnant woman has acquired a primary infection
during gestation or earlier. The classical approach is the detection of antimicrobial
immunoglobulin G (IgG) and IgM antibodies. Specific IgM is a sensitive indicator of
recent primary infection with all these microbes, yet the antibody can persist in the
blood for a long time (13–15) and can also reappear in HCMV or T. gondii secondary
infections. An approach for the dating of primary infection, e.g., with each of these
pathogens, is the measurement of the antigen-binding avidity (functional affinity) of
antimicrobial IgG. Upon initial antigenic challenge, IgG matures from low to high
avidity due to antigen-driven B-cell selection and narrowing of the range of epitopes.
This feature has been used in the clinical laboratory setting to distinguish between
acute and past immunity via the implementation of either of two approaches: the use
of a chaotropic agent to disrupt weak antigen-antibody interactions (16) or the addition
of antigens to the solution to compete for the capture of high-avidity antibodies (17).
Current serodiagnosis is mostly confined to the detection of one pathogen at a time.
A convenient approach for high-throughput antibody detection is a suspension immu-
noassay (SIA) employing flow cytometric analysis of fluorescent bead sets. In a previous
study, we developed SIAs for the simultaneous detection and identification of IgGs
against these three pathogens (18). In the present study, we employ this technology for
the simultaneous determination of antimicrobial IgMs. We furthermore introduce
corresponding chaotrope-based IgG avidity SIAs for the identification and timing of the
corresponding primary infections.
RESULTS
Diagnostic performances of IgM and IgG avidity SIAs. The diagnostic perfor-
mances of the assays were evaluated using different sample types that have been
stratified here into two panels (Table 1). Panel 1 includes archival serum samples
analyzed by high-standard commercial or in-house reference assays (see Materials and
Methods and Table S1 in the supplemental material). Panel 2 includes follow-up serum
samples from patients presenting with a profile of primary or secondary infection by
HCMV, T. gondii, or B19. The antimicrobial IgM SIAs were run in a multiplex format, and
the IgG avidity SIAs were run in a singleplex format.
TABLE 1 Sample panels used in the study
Sample panel and
pathogen studied Study population (references)
No. of
samples
Panel 1
HCMV Archival samples from HUSLAB 97
T. gondii Archival samples from HUSLAB 94
B19 Archival samples from HUSLAB 40
B19 87 medical students 87
Panel 2
HCMV 52 follow-up patients with HCMV primary or secondary infection (35, 41) 149
39 patients with primary infection 108
13 patients with secondary infection 41
T. gondii 22 follow-up pregnant women with T. gondii primary infection (19, 42) 116
9 pregnant women with IgM and low avidity of IgG in their first sample 48
13 pregnant women who were IgG seroconverters 68
B19 66 follow-up children and adults with B19 primary infection (18, 24, 25, 40) 126
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(i) Panel 1. (a) HCMV. Altogether, 97 samples were studied for IgM as well as for IgG
avidity, and results were compared to those of Abbott’s Architect assays. The IgM SIA
had an overall agreement of 97.9% (94/96 samples) (Table 2), and the IgG avidity SIA
had an overall agreement of 95.9% (93/97 samples) (Table 3). Among the latter four
serum samples, three showed low avidity in the SIA and high avidity in the Architect
assay, while the remaining sample showed borderline avidity in the SIA and low avidity
in the Architect assay. The third method (Vidas) showed low (two samples) or border-
line (two samples) avidity for these samples.
(b) T. gondii. IgM and IgG avidity were examined in 94 serum samples, and the
results showed full concordance with the corresponding Vidas results (Tables 2 and 3).
(c) B19. IgM was tested in 40 clinical samples and 87 samples from students, and the
results were compared to those of a reference IgM test (Table 2). The overall corre-
spondence was 98.4% (125/127). All the student samples were B19 IgM negative by
both the SIA and an enzyme immunoassay (EIA). Excluding three serum samples with
insufficient VP1u IgG in the SIA, the concordance between the SIA and the reference
IgG avidity assays was 96.8% (91/94) (Table 3).
TABLE 2 Assay performances of the IgM SIAs
Assay and result
No. of samples with result by the indicated
comparator assay
% positive
agreement
(95% CI)
% negative
agreement
(95% CI)
Overall agreement
(kappa value)
(95% CI)Positive Equivalent Negative
CMV IgM SIA Architect CMV IgM
Positive 42 1 1 97.7 (88.0–99.9) 98.1 (89.7–100) 0.96 (0.90–1)
Borderline 1 0 0
Negative 1 0 51
T. gondii IgM SIA Vidas Toxo IgM
Positive 46 1 0 100 (92–100) 100 (92–100) 1 (0.95–1)
Borderline 0 0 0
Negative 0 0 47
B19 IgM SIA Biotrin B19 IgM
Positive 37a 0 0 95 (83.1–99.4) 100 (95.9–100) 0.96 (0.91–1)
Borderline 1a 0 0
Negative 2a 0 87b
aSamples were tested with the Biotrin B19 IgM test.
bSamples were tested with an in-house B19 IgM test.
TABLE 3 Assay performances of the IgG avidity SIAs
Assay and result
No. of samples with result by the
indicated comparator assay
% positive
agreement
(95% CI)
% negative
agreement
(95% CI)
Overall agreement
(kappa value)
(95% CI)Low Equivalent High
CMV IgG avidity SIA Architect CMV IgG avidity
Low 37 0 3 100 (90.8–100) 94.9 (85.9–98.9) 0.91 (0.83–1)
Borderline 1 0 0
High 0 0 56
T. gondii IgG avidity SIA Vidas Toxo IgG avidity
Low 47 0 0 100 (92–100) 100 (92–100) 1.0 (0.95–1.0)
Borderline 0 0 0
High 0 0 47
B19 VP1 IgG avidity SIA In-house B19 IgG VP2 ETS/in-house
B19 VP1u IgG avidity EIA
Low 36a 0 0b 92.3 (79.1–98.4) 100 (93.5–100) 0.93 (0.86–1.0)
Borderline 1a 0 2b
High 2a 0 53b
aSamples were tested with an in-house B19 IgG VP2 ETS test.
bSamples were tested with an in-house B19 VP1u IgG avidity EIA.
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(ii) Panel 2. (a) HCMV. In total, 108 samples from 39 patients with symptomatic
primary infection were analyzed (Fig. 1). In the IgM SIA, positive results were found in
82.8% (48/58) of serum samples collected within 30 days of onset, in 94.6% (35/37) of
serum samples collected during 30 to 90 days of onset, and in 58.8% (7/13) beyond
90 days of onset (Table 4). Over 200 days, all the sera were IgM SIA negative (Fig. 1a).
The IgG avidity SIA showed low avidity in all 30 IgG-containing serum samples collected
FIG 1 IgM response to (a) and avidity of IgG for (b) CMV in 39 subjects with CMV primary infection
serologically monitored for up to 1,056 days (dots) and of 13 subjects with CMV secondary infection
(triangles). The y axis shows MFI values (a) and avidity indices (b) by SIAs, and the x axis shows days after
onset. The vertical dashed lines represent days 90 and 200 after the onset of symptoms. The horizontal
dashed lines depict the IgM or IgG avidity cutoff values in SIAs.
TABLE 4 IgM and IgG avidity SIA results with panel 2
Sampling
No. of samples with IgM SIA result
No. of samples with IgG
avidity SIA result
Positive Borderline Negative Low Borderline High
CMV
3 mo 83 0 12 53 3 5
3 moa 13 4 37 4 1 49
T. gondiib
3 mo 33 2 5 31 4 0
200 days 27 2 21 9 6 35
B19
3 mo 82 0 0 68 4 1
3 mo 11 1 32 0 2 42
aSamples collected from beyond 3 months of CMV primary and from CMV secondary infection.
bSamples collected from T. gondii study subgroups A and B.
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within 30 days of onset as well as in 74.2% (23/31) of the samples collected during
30 to 90 days. After 90 days, 53.8% (8/13) of the serum samples exhibited high
avidity in the SIA. Beyond 200 days, all six serum samples showed high avidity
(Fig. 1b). In addition, 41 samples from 13 patients with apparent reinfection/
reactivation were studied with SIAs; 24.3% (10/41) were IgM SIA positive or bor-
derline and overall showed lower IgM signals than in primary infections (Fig. 1a). All
41 samples exhibited a high avidity of IgG in the SIA, as they did in the reference
test (Fig. 1b) (Table 4).
(b) T. gondii. Subgroup A, comprising 48 samples from 9 patients with primary
infection, was examined. In the SIA, a significant increase in IgG avidity was observed
in 88.9% (8/9) of patients. All 11 samples collected within 90 days showed positive or
borderline IgM SIA results (Fig. 2a) as well as low avidity by the SIA (Fig. 2b). Of the
serum samples collected beyond 200 days, 80% (24/30) were still IgM SIA positive, and
one was borderline (Fig. 2a), while the IgG avidities were high and borderline in 73%
(22/30) and 13% (4/30) of the samples, respectively (Fig. 2b). Of the latter four
low-avidity samples (200 days), three came from a single patient (days 210, 232,
and 386).
Moreover, in T. gondii subgroup B, constituting 68 samples from 13 seroconverters,
examined with the SIA, 92.3% (12/13) of patients were IgM positive, and 76.9% (10/13)
exhibited a significant IgG avidity increase at follow-up. Among the 29 samples
collected within 90 days after T. gondii seroconversion, 82.8% (24/29) were IgM SIA
positive or borderline (Fig. 2c), and all 24 samples showed low (n 20) or borderline
FIG 2 IgM response to (a and c) and avidity of IgG for (b and d) T. gondii. (a and b) IgM and IgG avidity values in subgroup A (9 patients who initially had
low T. gondii avidity and were monitored for up to 603 days). (c and d) IgM and IgG avidity values in subgroup B (13 seroconverters monitored for up to 503 days
after IgG seroconversion). The y axis shows MFI values (a and c) and avidity indices (b and d) by SIAs, while the x axis indicates days after the first IgM-positive
sample (a and b) or days after IgG seroconversion (c and d). The vertical dashed lines represent days 90 and 200. The horizontal dashed lines depict the IgM
or IgG avidity cutoff values in the SIAs.
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(n 4) avidity by the SIA (Fig. 2d). Of the four samples with borderline avidity, two had
been collected exceptionally late, 15 and 27 weeks after the IgG-negative serum
samples were collected. Similar results were seen in the EIA (19). Of the 20 seropositive
samples collected beyond 200 days, 75% (15/20) were IgM SIA negative (Fig. 2c), and
65% (13/20) showed high avidity and 10% (2/20) showed borderline avidity (Fig. 2d) in
the SIA. All the samples collected beyond a year were of high avidity in the SIA, except
for one that was borderline (avidity index, 21%).
(c) B19. We tested 126 serum samples from 66 children or adults with symptomatic
B19 infection. In the SIA, B19 IgM was found in all 82 samples collected within 90 days
of onset. Of the 44 samples obtained after day 90, 72.7% (32/44) were IgM SIA negative
(Fig. 3a). All 61 serum samples collected within 30 days showed low avidity in the B19
SIA. Of the 12 samples collected at days 30 to 90, 58.3% (7/12) exhibited low avidity,
33% (4/12) exhibited borderline avidity, and 8.3% (1/12, on day 73) exhibited high
avidity (Fig. 3b). Beyond 90 days, all samples had high or borderline avidity in the SIA
(95.5% high and 4.5% borderline) (Fig. 3b and Table 4).
Heterologous IgM reactivity. Overall, heterologous IgM reactivities were observed
in 3.5% (25/709) of the samples in this study. Of these, 8 samples belonged to panel 1
(6 HCMV IgM positive with low IgG avidity and 2 HCMV IgM negative with high IgG
avidity), and 17 belonged to panel 2 (12 serum samples from 8 patients with HCMV
primary infection, 3 serum samples from 2 patients with HCMV secondary infection, and
2 samples from a single patient with T. gondii primary infection). Among the 25
samples, 13 presented with homologous (cf. IgM) IgG. To identify the origin of the
heterologous IgM reactivity, we performed multiplex IgG avidity SIAs and found that 11
samples showed high avidity against the homologous antigen, excluding recent pri-
FIG 3 IgM response to B19 VP2 (a) and avidity of IgG for B19 VP1u (b). Represented are the IgM
responses to B19 VP2 and IgG avidity for B19 VP1u in 80 subjects with symptomatic B19 infection
serologically monitored for up to 700 days. The y axis shows MFI values (a) and avidity indices (b) by SIAs,
and the x axis shows days after onset. The vertical dashed line represents day 90 after the onset of
symptoms. The horizontal dashed lines depict the IgM or IgG avidity cutoff values in the SIAs.
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mary infection by that pathogen (Tables 5 and 6). The other two samples were from a
patient with a profile of HCMV secondary infection and displayed IgG and IgM SIA
reactivities against B19 VP2 also. After retesting by the EIA, the VP2 IgM EIA was
positive, and the VP2 IgG epitope-type-specificity (ETS) index was 10. Hence, it was
apparent that this patient had a B19 primary infection inducing a serological pattern of
HCMV secondary infection.
Reproducibilities of SIAs. The intra- and interassay coefficients of variation (CVs) of
HCMV, T. gondii, and B19 IgM SIAs were assessed using serum pools containing or
lacking the specific IgMs. The respective intra-assay CVs were found to be 2 to 9%, 9 to
11%, and 6 to 9%, while the respective interassay CVs were 9 to 12%, 11 to 16%, and
11 to 14%. The respective interassay CVs of IgG avidity SIAs, assessed using acute-phase
and past-infection serum pools, were 9 to 18%, 14 to 19%, and 14 to 17%, respectively.
DISCUSSION
Combinations of serological tests are practicable for the detection of infections
during pregnancy (20–23). While IgM in general is a sensitive indicator of recent
primary infection, in many contexts, it lacks clinical specificity, hence calling for
additional markers for infection dating. In such combinatory or “reflex” diagnostics, a
feasible strategy is initial screening for antimicrobial IgG and IgM, in a multiplex format,
followed by retesting of the IgM-positive samples with a conceptually different test, in
singleplex, to attest the infection status. We have previously established microsphere-
based IgG assays for B19, HCMV, and T. gondii infections (18). In this study, for these
important pathogens, we successfully developed (i) IgM SIAs, for use as a primary
approach (including screening), as well as (ii) the corresponding IgG avidity SIAs, for
assessment of IgM-positive samples.
The new assays were validated here with 318 archival serum samples. Compared to
high-quality commercial or in-house assays, the respective positive and negative
percent agreements of the IgM SIAs were 95% to 100% and 98% to 100%, and those
of the IgG avidity SIAs were 92% to 100% and 95% to 100%. Excellent agreement was
seen between SIAs and reference assays for IgM (kappa coefficient 95% confidence
interval [CI], 0.96 to 1) and for IgG avidity (kappa coefficient 95% CI, 0.91 to 1). In
clarifying the B19 infection time, the new VP1u IgG avidity SIA also agreed well with the
TABLE 5 Singleplex and multiplex avidity study of samples with heterologous IgM
reactivities for HCMV, B19, and T. gondii
Study
cohort Sample type (day of onset)
Avidity index (%)
Singleplex
CMV assay
Multiplex assay
CMV B19 T. gondii
Panel 1 CMV IgM positive, low avidity of IgG 0.1 1.6 73.9
Panel 1 CMV IgM positive, low avidity of IgG 1.2 3 77.3 77.1
Panel 1 CMV IgM positive, low avidity of IgG 1.2 2 59
Panel 1 CMV IgM negative, high avidity of IgG 65.7 64.7 84.4
Panel 2 CMV primary infection (16) 1.9 2.5 34.2
Panel 2 CMV primary infection (68) 10.4 10.9 49.6
Panel 2 CMV primary infection (18) 2.2 2.8 77.4
Panel 2 CMV Primary infection (34) 1.8 4.7 84.4
Panel 2 CMV Primary infection (19) 12.8 9 157.0
TABLE 6 Singleplex and multiplex avidity study of samples with heterologous IgM
reactivities for T. gondii and B19
Study
cohort
Sample type (days after first
IgM-positive sample)
Avidity index (%)
Singleplex
T. gondii assay
Multiplex assay
T. gondii B19
Panel 2 T. gondii primary infection (0) 18 13.8 84.5
Panel 2 T. gondii primary infection (64) 6.5 6.6 76.9
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established EIA for the “conformation dependence” or “epitope type specificity” (ETS)
of VP2 IgG, divergent qualitative determinants of antimicrobial IgG maturing progres-
sively during the months since the first antigenic challenge (21, 24, 25).
Of note, the three HCMV IgG avidity tests used in the current study (SIA, Architect,
and Vidas) are technologically distinct: (i) while the SIA and Vidas are based on protein
denaturation, Architect utilizes antigen competition (17), and (ii) while Vidas and
Architect are based on single dilutions of serum (urea treated/reference), the SIA is
based on the endpoint titration of serum (dilution series). Notwithstanding the assay
type differences, in diagnostic performance, the HCMV SIA agreed well with the
corresponding Architect assay.
The IgM as well as the IgG avidity SIAs showed high clinical sensitivities among the
samples collected within 3 months of primary infection by HCMV, T. gondii, or B19.
Indeed, in HCMV and B19 IgG avidity SIAs, only beyond 2 months of symptom onset did
the first instances of high avidity appear. As both persisting and reappearing IgMs were
observed among these samples, the need for infection time verification became
substantiated. With the IgG avidity SIAs, more than 90% of samples collected beyond
3 months of primary infection by B19 or HCMV (including secondary responses of the
latter) were correctly identified (high avidity) as past infection. Likewise, the T. gondii
IgG avidity SIA could effectively distinguish acute from latent/chronic T. gondii infec-
tions; however, low-avidity IgG was seen in five patients beyond 200 days of primary
infection. Persistence of low-avidity IgG after T. gondii infection has been seen in many
studies, especially among pregnant women and in medicated patients (26–29). There-
fore, as pointed out previously (30), measurement of T. gondii IgG avidity serves better
in ruling out than ruling in a recently acquired infection. NB, even if the newly
developed assays in this study showed good reproducibility, the use of a calibrator
serum could further increase their precision, particularly for low-positive and borderline
results.
The antigens used for T. gondii IgM detection are usually tachyzoite lysates or
recombinant proteins (17, 19, 31). Here, we employed a tachyzoite lysate enriched in
membrane fractions, including the apical complex. The latter is associated with active
motility during parasite invasion and is a strong immunogen for IgM (32). Interestingly,
the presently generated IgM SIA based on this antigen showed 100% agreement with
the Vidas IgM test employing the tachyzoite lysate.
IgM antibodies appear in circulation not only after primary or secondary infection
but also as a result of polyclonal B-cell stimulation (33) with, e.g., transient heterologous
IgM reactivity induced by HCMV primary infection, as has been known for a long time
(34). Hence, the correct identification of the origin calls for another marker, such as a
qualitative characteristic of the antimicrobial IgG (35). Also, to this end, the presently
employed multiplex IgG avidity SIAs were shown to be suitable. In addition to field
diagnosis, the utility of IgG avidity multiplexing has been noted in vaccine develop-
ment (36).
Endpoint titration of serially diluted sera was successfully employed here in
microsphere-based IgG avidity measurements. While such a procedure is unaffected by
the IgG level in the sample, it calls for series of stepwise dilutions of the specimen. In
this regard, a simpler approach based on a single dilution (37) could be an interesting
choice for microsphere-based IgG avidity measurements.
Altogether, the IgM and IgG avidity SIAs were closely comparable to high-quality
reference assays in diagnostic performance, providing reliable and cost-effective means
for the diagnosis of B19, HCMV, and T. gondii infections. The new IgM assays were
highly sensitive in the detection of recent primary infections, as were the new IgG
avidity assays, which furthermore efficiently separated acute/primary infections from
distant/secondary infections. The strategy of IgG-IgM multiplex screening followed by
IgG avidity reflex testing provides a high-throughput, accurate means for the detection
and stage determination of B19, HCMV, and T. gondii infections.
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MATERIALS AND METHODS
Study samples and patients. (i) Panel 1. Panel 1 included 231 archival (20°C) serum samples sent
to the Helsinki University Central Hospital Laboratory Service (HUSLAB) for diagnostic evaluation be-
tween 2003 and 2013 as well as 87 samples collected from constitutionally healthy medical students
(Table 1). The main characteristics of the reference assays, including cutoffs, are summarized in Table S1
in the supplemental material.
(a) HCMV. Ninety-seven serum samples were examined for HCMV IgM antibodies and IgG antibody
avidity using the respective Architect assays as reference tests (Abbott). In the Architect HCMV IgM assay,
44 serum samples were positive, 1 was borderline, and 52 were negative. In the Architect HCMV IgG
avidity assay, 38 serum samples displayed low avidity, and 59 displayed high avidity. IgG avidity
discordances between the SIA and Architect were assessed with the Vidas assay (bioMérieux).
(b) T. gondii. Ninety-four serum samples were analyzed for T. gondii IgM antibodies and IgG avidity
using the Vidas Toxo IgM and IgG avidity assays as reference tests (bioMérieux). In the Vidas Toxo IgM
assay, 46 samples were positive, 47 were negative, and 1 was borderline. In the Vidas Toxo IgG avidity
assay, 47 serum samples were of low avidity, and 47 were of high avidity.
(c) B19. Forty serum samples were tested for B19 IgM antibodies by Biotrin’s B19 IgM assay (Liaison;
DiaSorin) as well as for VP2 IgG epitope type specificity (ETS) by an in-house ETS EIA (38). All 40 serum
samples showed the presence of B19 VP2 IgM antibodies and a low index of IgG ETS, indicating acute
infection. On the other hand, among the 87 medical students, 57 were seropositive for B19 VP2 IgG yet
devoid of VP2 IgM by the corresponding in-house EIAs (39). These 57 samples were studied for B19 IgG
avidity by a VP1u antigen-based EIA (21, 25, 40, 41); 56 exhibited high avidity, indicating past B19
infection, and 1 was borderline.
(ii) Panel 2. Panel 2 included 391 serum samples from 140 patients with primary or secondary
infections by HCMV, T. gondii, or B19. These patients and specimens have previously been examined
serologically for HCMV (35, 41), T. gondii (19, 42), or B19 (18, 24, 25, 40).
(a) HCMV. A total of 108 samples originated from 39 patients with HCMV primary infection (35, 41)
monitored serologically for up to 1,653 days. Among the samples, 58 had been collected within 30 days,
37 were collected within 30 to 90 days, and 13 were collected beyond 90 days from the onset of
symptoms. These 39 patients with HCMV primary infection were apparently immunocompetent, except
for a single heart transplant recipient. Moreover, 41 samples originated from 13 patients with a
serological profile of HCMV secondary infection (exogenous reinfection or endogenous reactivation) (41).
Of these 13 patients, 9 were transplant recipients (2 heart, 2 liver, 1 lung, 2 kidney, and 2 bone marrow
recipients). The serum samples had been collected between 1986 and 1997, and the number of samples
per patient ranged from 1 to 6.
(b) T. gondii. A total of 116 samples were obtained from 22 pregnant women with T. gondii primary
infection (29), of whom 9 individuals presented with specific IgM and low-avidity IgG in their first
samples, constituting subgroup A (n  48 samples). These patients had been monitored serologically for
a year (or more), except for one, who was monitored for 64 days. The other 13 patients were IgG
seroconverters monitored for up to 503 days, constituting subgroup B (n  68 samples). These serum
samples had been collected between 1989 and 1990 (19, 42). The number of serum samples per patient
ranged from 2 to 7.
(c) B19. A total of 126 serum samples were obtained from 66 children or adults (median age, 33 years;
range, 2 to 55 years) with symptomatic B19 infection. The patients had been monitored serologically for
up to 700 days. Collected between 1992 and 2001, there were 1 to 4 serum samples per patient (18, 24,
25, 40). Among the samples, 69 had been taken within 30 days, 13 samples were taken within 30 to
90 days, and 44 samples were taken beyond 90 days of onset.
(iii) Diagnostic criteria of infections (panel 2). (a) HCMV. The 39 patients with HCMV primary
infection presented with seroconversion of HCMV IgG and a low avidity of HCMV IgG in the first positive
sample, and 7 patients also had HCMV IgM seroconversion, whereas 32 patients were IgM positive or
borderline with the first sample. The 13 patients with a profile of HCMV secondary infection had a 4-fold
(or higher) increase of the HCMV IgG level, from the existing presence in the first sample of high-avidity
HCMV IgG. Nine of these patients showed IgM seroconversion, 2 were IgM borderline, and 2 remained
IgM negative.
(b) T. gondii. The 9 patients of T. gondii subgroup A exhibited T. gondii IgM as well as low-avidity IgG
in the first sample, and the 13 patients in subgroup B showed seroconversion of T. gondii IgG. The
seroconverters showed IgM seroconversion (n 3) or were IgM positive or borderline with the first
sample (n 9), while a single patient lacked IgM. All IgG seroconverters were of low or borderline avidity
with the first seropositive sample.
(c) B19. The 66 patients with recent B19 infection had B19 IgM (n 66) as well as seroconversion
(n 25) or a significant rise (n 41) in the level of B19 IgG and had low (15%) avidity or a low (10)
ETS EIA ratio in the first seropositive sample.
(iv) Ethics approval. The Helsinki University Hospital Ethics Committee accepted the use of clinical
samples in this study (Dnro 553/E6/2001, §106, 11.06.2014). The serum samples from medical students
were obtained with informed consent. All other samples in this study were taken as part of standard care
and were analyzed anonymously.
Microsphere-based suspension immunoassays. (i) Coupling of antigens to magnetic micro-
spheres. The coupling of antigens to carboxylated fluorescent microspheres (Luminex Corp., USA) was
performed according to the manufacturer’s protocol and as described previously by Wang et al. (18). The
coupled microspheres were stored in StabilGuard (SG) buffer (SurModics, USA) at 4°C in the dark. Optimal
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antigen concentrations were determined by titration (ranging from 200 to 0.8 g per 106 microspheres).
The conditions for each assay are presented in Tables 7 and 8.
(ii) Internal controls. (a) Naked microspheres. For specificity, each test run included control uncou-
pled (“naked”) microspheres stored in SG buffer (18).
(b) Rheumatoid factor (RF) control. In the IgM test, each sample was also tested with human IgG
(Sigma-Aldrich, USA)-coated microspheres to monitor the effectiveness of IgG removal (illustrated in
Fig. S1). The coupling and storage of IgG-coated microspheres were the same as those for the
antigen-coated magnetic microspheres (see above).
(iii) Multiplex IgM SIA. The multiplex IgM SIA included the removal of IgG with GullSORB (goat
anti-human IgG; Meridian Bioscience, USA). According to our previous determination, described in Text
S1 in the supplemental material, this pretreatment increased not only the specificity but also the
sensitivity of the IgM assays (Fig. S2). The conditions for each IgM assay are presented in Table 7. In brief,
GullSORB was mixed with serum, at a serum dilution of 1:20 (43). The mixture was kept at room
temperature for 1 h with shaking and then centrifuged at 14,000 g for 1 min to remove IgG
precipitates. The supernatant was further diluted 4-fold. Next, 50 l of this (1:80) IgG-depleted serum was
incubated with 1.75 103 antigen-coated (or control) microspheres/analyte/well for 45 min. After
washes, 50 l of biotinylated anti-human IgM (Sigma, USA) at 3 g/ml was added for 30 min. After
washes, 50 l of 6 g/ml streptavidin-conjugated phycoerythrin (SA-PE; Life Technologies, USA) in
phosphate-buffered saline (PBS) with 0.05% Tween 20 (PBST) was applied for 20 min. After final washes,
each well was resuspended in 120 l of PBST and read on a Bio-Plex 200 instrument (Bio-Rad). The
median fluorescence intensity (MFI) values were determined.
(iv) Heterologous IgM reactivity. Heterologous IgM reactivity among the three microbes was
observed in 25 samples of this entire study. To identify the original immunoactivity, we employed a
multiplex IgG avidity SIA (see below) for the simultaneous determination of infection stages of the three
pathogens. In addition, two samples showing SIA IgG and IgM responses against B19 VP2 but not VP1u
were resolved by IgM and VP2 ETS EIAs.
(v) IgG avidity SIAs (singleplex/multiplex). The IgG avidity SIAs are based on the principle of
elution of the antigen-bound antibodies with urea (Fig. 4), under the experimental conditions presented
in Table 8. Briefly, from each serum sample, two dilution series were made in PBST, series 1 (1:20, 1:80,
1:320, and 1:1,280) and series 2 (1:80, 1:320, 1:1,280, and 1:5,120). These dilutions were placed into a
96-well plate and incubated with 1.75 103 antigen-coated microspheres/well/analyte for 45 min. Next,
series 1 samples were washed three times for 5 min each with 6 M freshly prepared urea (Promega, USA)
TABLE 7 Antigens and suspension immunoassay conditions for IgM assays
Assay Antigen
Concn
(g)/million
microspheres Source
Cutoff determination
Cutoff
criterion
Reference
value MFI
No. of
seronegative
samples
CMV IgM Viral lysate (strain AD 169) 25 Advanced
Biotechnologies
2 SD Negative, 518 60
3 SD Positive, 631
T. gondii IgM T. gondii (RH strain)
lysate enriched in
membrane fraction,
IgM grade
6 Microbix
Biosystems
4 SD Negative, 938 60
5 SD Positive, 1,056
B19 VP2 IgM In-house insect cell
recombinant VP2
6 In-house 4 SD Negative, 714 86
5 SD Positive, 831
TABLE 8 Antigens and suspension immunoassay conditions for IgG avidity assays
Assay Antigen
Concn
(g)/million
microspheres Source
Cutoff determination
Cutoff
criterion
Reference
value index
Primary infection
Time
No. of
samples
CMV IgG avidity Viral lysate
(strain AD 169)
20 Advanced
Biotechnologies
2.5 SD Acute, 15 50 days 45
4 SD Past, 21
T. gondii
IgG avidity
T. gondii (RH strain)
tachyzoite lysate
12.5 Microbix
Biosystems
3 SD Acute, 20 3 mo 34
4 SD Past, 25
B19 VP1u
IgG avidity
Prokaryotic recombinant
fusion protein containing
the B19 VP1 unique region
50 In-house 3.5 SD Acute, 38 28 days 60
4.5 SD Past, 44
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in PBS, as opposed to series 2, with PBS only. Subsequently, biotinylated protein G (Thermo Scientific,
USA) and SA-PE were added, and the MFIs were measured, as for the IgG SIAs (18).
(vi) Calculation of IgG avidity values. The IgG avidity values here are the ratios of endpoint titers
of series 1 (urea treated) over those of series 2 (non-urea treated), calculated by the curve-fitting software
Avidity 1.2 (41).
(vii) Cutoff determination. The IgM SIA cutoffs were set at the mean MFIs plus 2 to 5 standard
deviations (SDs) of negative controls. For B19, the cutoff was determined with 86 serum samples lacking
specific antibodies according to Biotrin’s B19 IgG and IgM EIAs (18, 39). For HCMV and T. gondii, the
cutoffs were defined with separate sets of 60 serum samples shown to lack the respective antibodies by
the corresponding Architect IgG and IgM tests (18). The IgM cutoff criteria and values are presented in
Table 7.
The cutoff values for low and high avidities of IgG for B19, HCMV, and T. gondii are presented in
Table 8. For B19 and HCMV, the primary-infection samples were taken within 28 to 50 days after the onset
of symptoms, and for T. gondii, samples were taken within 3 months after seroconversion. As defined
previously (19), an increase in IgG avidity values (percent units) of 10, and simultaneously 2-fold or
more, in paired samples (collected within 200 days) was considered significant.
(viii) Reproducibility. The intra-assay variability for the IgM SIA was calculated with 8 replicates in
the same run, and interassay variability was calculated with 6 distinct runs, employing serum pools
containing or lacking the respective IgM. Interassay variability for the IgG avidity SIA was evaluated with
6 to 10 distinct runs during 3 months, using pools containing acute-phase or past-infection serum
samples.
(ix) Statistical analysis. The positive percent agreement, negative percent agreement, and kappa
values between SIAs and the reference assays were calculated with serum panel 1. For the statistical
calculations, borderline values in IgM SIAs were considered positive, given the primary role of IgM assays
in screening. In IgG avidity SIAs, in turn, borderline-avidity values were considered high-avidity values,
due to the important role of these assays in ruling out recent primary infections (30). All the analyses
were calculated by 2-by-2 contingency table analysis in GraphPad Prism (GraphPad Software, USA). The
overall agreements between SIAs and EIAs were evaluated by kappa values and defined as poor (kappa
value of 0.20), fair (0.21 to 0.40), moderate (0.41 to 0.60), good (0.61 to 0.80), and very good (0.81 to
1.00) (44).
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